title: Paraneoplastic disorders.
abstract: OBJECTIVE
  Paraneoplastic disorders are autoimmune diseases associated with risks for specific cancers and marked by specific autoantibodies. They cause diverse clinical syndromes of the central and peripheral nervous systems.
  
  
  RESULTS
  In the peripheral nervous system, autoimmunity to synaptic or axonal proteins has long been recognized to associate with specific cancers. In these disorders, typified by myasthenia gravis, the antibodies are directly toxic, and recovery with immunotherapy is the rule. In contrast, the classic paraneoplastic syndromes involve a higher risk of cancer, autoantibodies to intracellular proteins (eg, Hu proteins), T-cell-dependent disease mechanisms targeting the CNS or peripheral nervous system, and a poor response to treatment. Following the discovery of N-methyl-D-aspartate (NMDA) receptor antibodies, a new and expanding group of disorders involving autoantibodies to CNS synaptic and neuronal membrane proteins and a favorable response to immunotherapy emerged. A final group of disorders involves antibodies to intracellular synaptic proteins, such as glutamic acid decarboxylase 65 (GAD65), and it is unclear whether these diseases involve antibody or T-cell mechanisms.
  
  
  CONCLUSIONS
  Neurologists should recognize the clinical syndromes associated with paraneoplastic disorders, utilize autoantibody and other testing to confirm the diagnosis, understand the pathologic basis of the diseases, and promptly give appropriate therapies.
authors.forename: Eric
authors.initials: E
authors.lastname: Lancaster
mesh_terms: D001323:Autoantibodies / Q000276:immunology*; D004268:DNA-Binding Proteins / Q000276:immunology; D003937:Diagnosis, Differential; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008565:Membrane Proteins / Q000276:immunology; D009157:Myasthenia Gravis / Q000150:complications / Q000276:immunology; D009369:Neoplasms / Q000209:etiology*; D020361:Paraneoplastic Syndromes, Nervous System / Q000150:complications* / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology; D012307:Risk Factors
chemical_list: D001323:Autoantibodies; D004268:DNA-Binding Proteins; D008565:Membrane Proteins; D016194:Receptors, N-Methyl-D-Aspartate; D005968:Glutamate Decarboxylase
references.citation: Brain. 2001 Jun;124(Pt 6):1138-48
references.pmid: 11353730
references.citation: Brain. 2012 Nov;135(Pt 11):3453-68
references.pmid: 23065479
references.citation: Eur J Neurol. 2006 Aug;13(8):809-18
references.pmid: 16879290
references.citation: Brain. 2004 Aug;127(Pt 8):1831-44
references.pmid: 15215214
references.citation: J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):412-6
references.pmid: 18931014
references.citation: JAMA Neurol. 2013 Apr;70(4):506-9
references.pmid: 23400636
references.citation: J Immunol. 2013 Dec 1;191(11):5524-41
references.pmid: 24184556
references.citation: Ann Neurol. 2001 Sep;50(3):301-11
references.pmid: 11558786
references.citation: Ann Neurol. 2003 May;53(5):580-7
references.pmid: 12730991
references.citation: Ann Neurol. 2003 Mar;53(3):325-36
references.pmid: 12601700
references.citation: Ann Neurol. 2012 Jun;71(6):815-24
references.pmid: 22447725
references.citation: Neurology. 2008 Oct 14;71(16):1291-2
references.pmid: 18852446
references.citation: Lancet Neurol. 2014 Feb;13(2):167-77
references.pmid: 24360484
references.citation: J Neurosci. 2013 Nov 13;33(46):18161-74
references.pmid: 24227725
references.citation: Brain. 2010 Sep;133(9):2734-48
references.pmid: 20663977
references.citation: Ann Clin Transl Neurol. 2014 Mar 1;1(3):180-189
references.pmid: 24707504
references.citation: JAMA Neurol. 2014 Aug;71(8):1009-16
references.pmid: 24934144
references.citation: Neurology. 2013 Oct 22;81(17):1500-6
references.pmid: 24068784
references.citation: Lancet Neurol. 2011 Jan;10(1):63-74
references.pmid: 21163445
references.citation: Neurology. 1992 Oct;42(10):1931-7
references.pmid: 1407575
references.citation: Lancet Neurol. 2014 Mar;13(3):276-86
references.pmid: 24462240
references.citation: J Immunol. 2010 May 1;184(9):4863-70
references.pmid: 20348424
references.citation: Neurology. 2011 Nov 1;77(18):1698-701
references.pmid: 22013185
references.citation: Ann Neurol. 2000 Mar;47(3):297-305
references.pmid: 10716248
references.citation: Eur J Neurosci. 2010 Jul;32(2):298-309
references.pmid: 20646055
references.citation: Ann Neurol. 2012 Aug;72(2):241-55
references.pmid: 22473710
references.citation: Ann Neurol. 2009 Apr;65(4):424-34
references.pmid: 19338055
references.citation: J Rheumatol. 2008 Mar;35(3):438-44
references.pmid: 18203322
references.citation: Ann Neurol. 2005 Jul;58(1):96-107
references.pmid: 15984030
references.citation: Ann N Y Acad Sci. 2003 Sep;998:211-4
references.pmid: 14592878
references.citation: Autoimmun Rev. 2013 Jul;12(9):875-84
references.pmid: 23535159
references.citation: J Womens Health (Larchmt). 2009 Mar;18(3):311-9
references.pmid: 19281314
references.citation: J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):767-73
references.pmid: 18223018
references.citation: J Neurol. 2010 Jan;257(1):59-62
references.pmid: 19629562
references.citation: Mayo Clin Proc. 2006 Sep;81(9):1207-14
references.pmid: 16970217
references.citation: Neurology. 2007 Jan 16;68(3):239-40
references.pmid: 17224583
references.citation: Lancet Neurol. 2010 Aug;9(8):776-85
references.pmid: 20580615
references.citation: Lancet Neurol. 2011 Dec;10(12):1098-107
references.pmid: 22094130